Eton Pharmaceuticals, Inc.

# Signal Note: EcoR1 Capital Initiates $34.3M Position in ETON EcoR1's entry into Eton suggests conviction in the company's late-stage pipeline, likely driven by near-term catalysts around ETON-01 (ETO for autoimmune conditions) or other clinical readouts expected within 12-24 months. The $34.3M position size indicates meaningful conviction from a growth-focused investor with strong biotech selection track record, though this represents a modest stake requiring monitoring of additional institutional demand for validation.